Bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, is increasingly recognized as standard of care for the treatment of metastatic colorectal cancer in a first-line setting, with reasonable biological implications [10,11]. Here, VEGFA is linked to metastatic colorectal cancer.